Shares of Bristol-Myers Squibb Company (NYSE:BMY) traded today at $77.84, eclipsing its 12-month high. Approximately 5.2 million shares have changed hands today, as compared to an average 30-day volume of 15.4 million shares.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Bristol-Myers Squibb Company is currently priced 3.2% above its average consensus analyst price target of $75.19.
Over the past year, Bristol-Myers Squibb Company has traded in a range of $53.22 to $77.84 and is now at $77.66, 46% above that low.
About BillionDollarClub
BillionDollarClub (BDC) is the exclusive home of the biggest and brightest companies covered by IBN, a financial news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution to nearly 2 million followers, and (5) a full array of corporate communications solutions. This is the place you want to be, where every covered company has a market cap in excess of $1 billion. By cutting through the overload of information in today’s market, BDC brings its clients unparalleled visibility, recognition and brand awareness. While IBN’s client list includes companies big and small, BillionDollarClub is the gold standard.
To receive SMS text alerts from BillionDollarClub, text “Billion” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BillionDollarClub.com
Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: http://IBN.fm/Disclaimer
BillionDollarClub (BDC)
Los Angeles, California
www.BillionDollarClub.com
310.299.1717 Office
Editor@BillionDollarClub.com
BillionDollarClub is part of the InvestorBrandNetwork.
The company has initiated cell line development for its lead BiTAC(R) T-cell engager program, selecting…
France will relaunch the country’s social leasing electric vehicle (EV) program on July 16, 2026…
South Korea has announced one of its biggest technology investment plans ever. The country plans…
Jefferies Financial may not be as large as Wall Street giants like Goldman Sachs, Morgan…
Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics, with pharmaceutical…
A new study has revealed that a sodium-ion battery made by Chinese manufacturer Hina has…